- recruitingPHASE2, PHASE3
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This study looks into new treatments for a rare, inherited form of Alzheimer's disease. Researchers want to see if these drugs can stop or slow down the disease in people who are at high risk or in the very early stages, based on their family history and genes.
United States · Argentina · Australia - recruitingPHASE3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study helps find people who might be suitable for future Alzheimer's disease research. It's like a first step to see if your memory concerns mean you could join other studies looking for new ways to treat Alzheimer's. You won't receive new treatments in this initial check.
United States · Argentina · Australia - active not recruitingPHASE3
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This study is testing a new medication called Trontinemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and effective in slowing down memory and thinking problems. They will compare it to a dummy drug (placebo).
United States · Argentina · Australia - active not recruitingPHASE2, PHASE3
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
This study is for people at risk for, or with, a specific early-onset Alzheimer's disease caused by a faulty gene. It tests if new medications can slow down memory and thinking problems, or improve markers of the disease, checking their safety and how well people tolerate them.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This study is testing a new drug called RO7126209 for people with early Alzheimer's disease. We want to see how safe it is, how well the body handles it, and if it affects the disease. Participants will receive the drug intravenously.
United States · Australia · Canada - recruitingPHASE2, PHASE3
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This study is looking into a new treatment called remternetug for people who are at risk of developing a specific type of early-onset Alzheimer's disease due to their genes. It aims to see if the treatment can slow down or stop the disease before symptoms appear.
United States · Argentina · Australia - active not recruitingPHASE2, PHASE3
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
This study is for people with a genetic form of early-onset Alzheimer's to test new medicines (E2814, Lecanemab) to see if they can slow down the disease. Researchers will check if these treatments improve brain markers and thinking skills.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This study is looking into a new treatment called Trontinemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow down symptoms compared to a dummy treatment (placebo).
United States · Argentina · Brazil - not yet recruiting
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
This study is gathering real-world information on a new Alzheimer's drug called LEQEMBI. It's looking at how safe the drug is and if there are any side effects, especially brain swelling or bleeding, in people using it as part of their regular care.
United Kingdom